
# **Cancer in Manitoba**

**2019 ANNUAL STATISTICAL REPORT** 



CancerCareManitoba
ActionCancerManitoba

<b>Table of Contents</b>	
Introduction to the Data	2
Manitoba's Cancer Profile	
Facts & Figures	3
Most Common Cancers, 2019	3
Cancer Incidence by Site	4
cancer incidence by Site	7
Manitoba Cancer Rates by Regional	
Health Authority (Incidence)	5
Cancer Incidence—Cases & Rates by Site	6
Tumour Staging by Site	8
Deaths by Underlying Cause in	
Manitoba (Mortality)	10
Appendix 1	
International Classification	
Of Disease for Oncology, 3rd Edition	11

### **Vision**

A world free of cancer

### Mission

To reduce and, where possible, eliminate the burden of cancer on the people of Manitoba through exemplary programs of prevention, diagnosis, treatment, rehabilitation, continuing care, research and education.

#### Introduction to the Data

The Manitoba Cancer Registry is an essential tool for evidence-based, data-driven decision making that has an immense impact on treatment and research. This year's report is based on the following information.

NOTE: All statistics in the body of this report only include Manitoba residents.

#### Manitoba Cancer Registry data is used for:

- health care planning and monitoring
- surveillance and studies on the causes and prevention of cancer, cancer clusters, treatment patterns, outcomes and survival
- patient care
- quality assurance
- reporting to the Canadian Cancer Registry, the North American Association of Central Cancer Registries and the International Association of Cancer Registries

#### Information sources include:

- provincial cytology and pathology departments
- admission/separation data from the provincial hospital abstracting system
- Manitoba Provincial Client Registry
- letters and "Report of Malignant Neoplasm Forms" from physicians and other health care providers
- hospital health records
- correspondence from other provincial and territorial cancer registries on Manitoba residents diagnosed and/or treated in those jurisdictions

#### Incidence data

Incidence refers to the number of new cases of cancer diagnosed in Manitoba every year. Cancer cases referenced were diagnosed in the 2019 calendar year. Incidence is also provided by stage of disease at diagnosis.

The Manitoba Cancer Registry uses disease site groupings according to the International Classification of Diseases for Oncology Third Edition (ICD-O3), based on Surveillance Epidemiology and End Results (SEER) Groups. See Appendix 1 for the primary site groupings used for incidence.

#### Mortality data

Mortality information refers to Manitobans who died of cancer in the 2019 calendar year, however, those patients may not have been diagnosed in 2019. The Vital Statistics Agency of Manitoba reported cancer as the leading cause of death in the province. In 2019, there were 2,864 deaths due to invasive cancer (age standardized rate – 208.6 per 100,000). The totals in the summary on page 10 include all cancer deaths occurring in Manitoba.

#### Rates

Incidence counts and rates are presented in this report. Annual age-standardized rates are per 100,000 population and allow for comparison of cancer rates in different regions with different age structures. Rates are age-standardized (using the direct method) to the 2011 Manitoba population.

#### Staging data

The Manitoba Cancer Registry has collected cancer stage for all cases of cancer (excluding non-melanoma skin cancer) diagnosed since January 1, 2004. From 2004 to 2017, collection followed the Collaborative Staging method consistent with the American Joint Committee on Cancer (AJCC) 6th and 7th Tumour, Nodes, and Metastases (TNM) editions. For cancer cases diagnosed January 1, 2018 and forward, cancer stage data is being collected following the AJCC 8th edition of the TNM manual.

In this report, stage data is shown for all disease site groups with a cancer incidence of 45 cases per year or more and is represented using pie charts. Stage information, along with frequency of incidence for each of these sites, can also be found in table format on page 8. Due to changes in the staging system, this year we have presented data as early and intermediate stage, and late stage.

#### **Population data**

Data are based on Manitoba estimates provided by Manitoba Health.

Additional statistical information is available upon request. Please contact the Manitoba Cancer Registry at:

1-877-787-1272 (toll-free), or CCMBepireg@cancercare.mb.ca

#### **Manitoba's Cancer Profile**

### **Facts & Figures**

#### Manitoba's cancer profile

Cancer is a significant health issue. In 2019, 12,134 Manitobans were diagnosed with cancer:

- **7,165** invasive cancers
- 4,498 in situ (confined to the area of origin)
- **349** unspecified cancers
- 122 benign brain and CNS (central nervous system)

In this same year, **2,864** people died from the disease.

The number of cancer cases in Manitoba is influenced by three factors:

- the age of the population
- the size of the population
- risk factors such as unhealthy living (including smoking, poor diet, inactivity, sun exposure), some environmental carcinogens, genetic predisposition and not being screened.


## Most Common Cancer Diagnoses, 2019


#### Incidence


Male		Female		Total	
SITE	CASES	SITE	CASES	SITE	CASES
Prostate	950	Breast	1008	Breast	1010
Lung & bronchus	468	Lung & bronchus	501	Lung & bronchus	969
Colorectal	456	Colorectal	388	Prostate	950
Kidney	201	Corpus uteri	269	Colorectal	844
Non-Hodgkin Lymphoma	187	Thyroid	134	Non-Hodgkin Lymphoma	315
Melanoma of the skin	165	Non-Hodgkin Lymphoma	128	Kidney	292
Bladder	110	Melanoma of the skin	126	Melanoma of the skin	291
Pancreas	88	Kidney	91	Corpus uteri	269
Stomach	78	Pancreas	86	Pancreas	174
Esophagus	65	Ovary	82	Thyroid	168

## **Cancer Incidence by Site**


### Invasive cancers only







## **Manitoba Cancer Rates by Regional Health Authority**




## 2019 All Invasive Cancers Female *Incidence*

Age-standardized rate per 100,000 Standard population: Manitoba 2011 Out-of-province residents excluded

### 2019 All Invasive Cancers Male *Incidence*

Age-standardized rate per 100,000 Standard population: Manitoba 2011 Out-of-province residents excluded



### Cancer Incidence - Cases and Rates in Manitoba by Site, 2019

												Ą	ge gro	up									т	otal Co	unt		ASIR*	
	Cancer Site		00-29	_		30-39			40-49	_		50-59			60-69	ı		70-79			80+							
		M	F	T	М	F	T	М	F	Т	M	F	Т .	М	F	Т	M	F	T	M	F	Т	М	F	T	М	F	Т
	Lip	0	0	0	0	0	0	2	1	3	2	2	4	8	4	12	14	3	17	10	7	17	36	17	53	5.39	2.18	3.62
	Tongue	0	1	1	0	1	1	2	0	2	10	3	13	12	5	17	7	5	12	0	1	1	31	16	47	4.31	2.07	3.19
Pharynx	Major salivary gland	0	0	0	1	0	1	0	0	0	1	1	2	2	2	4	1	0	1	2	1	3	7	4	11	1.06	0.53	0.76
& Pha	Floor of mouth	0	0	0	0	0	0	0	0	0	1	0	1	1	2	3	0	1	1	0	0	0	2	3	5	0.28	0.36	0.33
Buccal Cavity &	Gum & other mouth	0	0	0	0	1	1	0	2	2	1	0	1	2	4	6	3	5	8	0	2	2	6	14	20	0.79	1.77	1.32
Buccal	Nasopharynx	0	1	1	1	1	2	0	1	1	2	0	2	3	1	4	0	0	0	0	0	0	6	4	10	0.83	0.58	0.7
	Oropharynx	0	0	0	0	0	0	2	0	2	1	0	1	9	0	9	1	2	3	0	0	0	13	2	15	1.76	0.23	0.99
	Hypopharynx	0	0	0	0	0	0	1	0	1	1	0	1	2	1	3	7	0	7	1	0	1	12	1	13	1.66	0.12	0.84
	Other buccal cavity & pharynx	0	0	0	0	0	0	2	0	2	7	1	8	11	2	13	0	0	0	2	0	2	22	3	25	3.21	0.4	1.76
	Esophagus	0	0	0	0	0	0	1	0	1	11	4	15	30	5	35	14	7	21	9	3	12	65	19	84	9.24	2.41	5.62
	Stomach	0	0	0	4	0	4	3	4	7	13	8	21	20	8	28	24	16	40	14	5	19	78	41	119	11.4	5.34	8.09
	Small intestine	0	0	0	0	0	0	2	1	3	3	4	7	11	4	15	3	3	6	4	4	8	23	16	39	3.36	2.12	2.7
	Colorectal	1	4	5	10	9	19	28	13	41	87	49	136	128	91	219	126	112	238	76	110	186	456	388	844	67.07	49.25	57.79
tive	Colon excluding rectum	0	3	3	7	7	14	14	8	22	41	36	77	80	63	143	88	86	174	50	90	140	280	293	573	40.8	37.07	39.03
Digestive	Rectum & rectosigmoid	1	1	2	3	2	5	14	5	19	46	13	59	48	28	76	38	26	64	26	20	46	176	95	271	26.05	12.18	18.76
	Anus	0	0	0	0	0	0	1	1	2	3	2	5	1	3	4	0	7	7	3	6	9	8	19	27	1.34	2.39	1.91
	Liver	0	2	2	0	0	0	2	0	2	16	5	21	16	8	24	17	6	23	6	2	8	57	23	80	8.2	3.01	5.45
	Gallbladder	0	0	0	0	0	0	0	0	0	1	1	2	1	4	5	1	1	2	1	12	13	4	18	22	0.61	2.25	1.58
	Pancreas	0	1	1	1	1	2	3	0	3	13	10	23	29	22	51	25	19	44	17	33	50	88	86	174	12.85	10.83	11.89
	Other digestive system	0	0	0	2	0	2	2	2	4	4	5	9	14	8	22	10	14	24	8	11	19	40	40	80	5.84	5.05	5.43
λıα	Larynx	0	0	0	0	0	0	0	0	0	5	1	6	19	0	19	3	2	5	6	0	6	33	3	36	4.75	0.38	2.42
Respiratory	Lung & bronchus	0	1	1	1	1	2	4	4	8	47	53	100	140	145	285	173	187	360	103	110	213	468	501	969	68.11	62.03	64.33
Re	Other respiratory system	1	1	2	0	1	1	2	1	3	3	0	3	2	0	2	0	0	0	3	0	3	11	3	14	1.78	0.45	1.05
	Bones & joints	1	5	6	0	0	0	1	0	1	3	0	3	0	0	0	1	1	2	0	0	0	6	6	12	0.91	0.89	0.89
& soft heart)	Soft tissue (Including heart)	2	3	5	3	3	6	2	1	3	5	5	10	8	7	15	9	2	11	7	3	10	36	24	60	5.34	3.28	4.17
thelial (inc.	Kaposi sarcoma	0	0	0	0	0	0	0	0	0	1	0	1	1	0	1	0	0	0	0	0	0	2	0	2	0.28	0	0.14
Mesot	Mesothelioma	0	0	0	0	0	0	0	0	0	3	1	4	4	1	5	4	0	4	5	1	6	16	3	19	2.46	0.41	1.32
	Melanoma of the skin	0	1	1	3	15	18	14	16	30	29	22	51	46	30	76	45	26	71	28	16	44	165	126	291	24.28	16.89	20.1
	Breast	0	4	4	0	31	31	0	103	103	0	189	189	0	298	298	1	242	243	1	141	142	2	1008	1010	0.32	133.15	69.67
	Cervix uteri	0	3	3	0	16	16	0	11	11	0	6	6	0	14	14	0	4	4	0	1	1	0	55	55	0	7.67	0
nital	Corpus uteri	0	0	0	0	7	7	0	21	21	0	67	67	0	88	88	0	60	60	0	26	26	0	269	269	0	35.83	0
Female genital	Uterus, NOS	0	0	0	0	0	0	0	1	1	0	2	2	0	3	3	0	2	2	0	0	0	0	8	8	0	1.08	0
Fen	Ovary	0	5	5	0	3	3	0	7	7	0	18	18	0	17	17	0	21	21	0	11	11	0	82	82	0	11	0
	Other female genital system	0	0	0	0	0	0	0	4	4	0	7	7	0	12	12	0	8	8	0	8	8	0	39	39	0	5.14	0

												Ą	ge gro	up									_	-4-1 0	4		AO/D+	
	Cancer Site		00-29			30-39			40-49			50-59	)		60-69			70-79			80+		T	otal Co			ASIR*	
		M	F	T	M	F	T	М	F	Т	М	F	T	М	F	Т	М	F	Т	M	F	T	М	F	Т	М	F	Т
_	Prostate	0	0	0	0	0	0	7	0	7	114	0	114	372	0	372	301	0	301	156	0	156	950	0	950	135.16	0	0
Male genital	Testis	16	0	16	15	0	15	4	0	4	5	0	5	2	0	2	2	0	2	1	0	1	45	0	45	6.54	0	0
Male	Penis	0	0	0	0	0	0	1	0	1	2	0	2	2	0	2	3	0	3	1	0	1	9	0	9	1.31	0	0
	Other male genital system	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	1	0	1	0.13	0	0
	Bladder	0	0	0	0	0	0	4	1	5	8	4	12	20	7	27	38	12	50	40	14	54	110	38	148	17.09	4.75	10.13
Urinary	Kidney	0	3	3	5	1	6	16	4	20	53	28	81	61	23	84	41	25	66	25	7	32	201	91	292	29.44	12.21	20.27
Uri	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	4	1	5	5	1	6	0.91	0.12	0.44
	Other urinary system	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	1	1	2	3	1	4	4	3	7	0.71	0.39	0.5
S	Eye	0	0	0	0	0	0	0	1	1	1	0	1	0	3	3	1	2	3	1	1	2	3	7	10	0.48	0.88	0.68
Brain & other CNS	Brain	9	8	17	6	1	7	1	1	2	17	6	23	7	9	16	12	8	20	8	8	16	60	41	101	8.94	5.49	7.14
0	Other nervous system	4	0	4	0	1	1	2	0	2	2	0	2	0	1	1	0	0	0	0	0	0	8	2	10	1.23	0.26	0.75
crine	Thyroid	1	16	17	2	21	23	10	21	31	6	28	34	7	24	31	6	21	27	2	3	5	34	134	168	5.03	18.87	11.98
Endocrine	Other endocrine	2	3	5	0	0	0	2	1	3	0	0	0	0	1	1	0	1	1	0	0	0	4	6	10	0.62	0.86	0.75
e e	Hodgkin lymphoma	2	7	9	4	3	7	1	4	5	1	2	3	1	2	3	0	0	0	0	2	2	9	20	29	1.29	2.95	2.14
Lymphoma	Non-Hodgkin lymphoma	4	2	6	12	3	15	11	5	16	37	19	56	46	26	72	54	38	92	23	35	58	187	128	315	27.02	16.38	21.6
Ly	Multiple myeloma	0	0	0	1	0	1	1	4	5	6	8	14	21	14	35	18	9	27	15	8	23	62	43	105	9.13	5.66	7.13
	Acute lymphocytic leukemia	9	2	11	0	1	1	0	0	0	0	2	2	1	0	1	1	0	1	0	0	0	11	5	16	1.59	0.76	1.18
	Chronic lymphocytic leukemia	0	0	0	0	0	0	0	0	0	7	2	9	8	10	18	12	7	19	8	5	13	35	24	59	5.2	2.96	3.96
mias	Acute myeloid leukemia	3	1	4	0	0	0	4	2	6	3	4	7	8	5	13	13	9	22	6	3	9	37	24	61	5.41	3.12	4.16
Leukemias	Acute monocytic leukemia	0	0	0	1	0	1	0	0	0	1	0	1	0	0	0	1	0	1	1	0	1	4	0	4	0.61	0	0.28
	Chronic myeloid leukemia	2	0	2	2	0	2	0	0	0	3	1	4	2	1	3	5	0	5	2	2	4	16	4	20	2.32	0.53	1.39
	Other leukemias	1	0	1	1	0	1	1	1	2	1	2	3	3	2	5	2	0	2	1	1	2	10	6	16	1.44	0.85	1.13
	Other ill defined & unknown	3	0	3	3	3	6	1	1	2	13	8	21	31	24	55	52	30	82	37	43	80	140	109	249	20.84	13.52	16.87
	TOTAL - ALL INVASIVE	61	74	135	78	124	202	140	240	380	553	581	1134	1113	941	2054	1053	919	1972	640	648	1288	3638	3527	7165	529.67	459.69	488.6
	Non-Melanoma skin & in situ skin	7	9	16	26	41	67	77	80	157	238	225	463	483	380	863	658	429	1087	496	464	960	1985	1628	3613	296.42	208.53	246.97
	Breast in situ	0	0	0	0	3	3	0	6	6	0	31	31	0	46	46	0	27	27	0	3	3	0	116	116	0	15.39	7.86
	Cervix in situ	0	152	152	0	150	150	0	59	59	0	31	31	0	19	19	0	2	2	0	0	0	0	413	413	0	60.78	0
In situ	Prostate in situ	0	0	0	0	0	0	0	0	0	2	0	2	10	0	10	3	0	3	0	0	0	15	0	15	1.97	0	0
	Bladder in situ	1	0	1	0	2	2	9	1	10	20	4	24	47	17	64	55	13	68	32	13	45	164	50	214	23.98	6.25	14.41
	Colorectal in situ	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Other in situ (Excl. Breast, Skin, Cervix, Prostate, Bladder, Colorectal)	0	1	1	2	8	10	1	11	12	4	19	23	6	26	32	13	21	34	7	8	15	33	94	127	4.85	12.61	8.72
	TOTAL - ALL INVASIVE + IN SITU	69	236	305	106	328	434	227	397	624	817	891	1708	1659	1429	3088	1782	1411	3193	1175	1136	2311	5835	5828	11663	856.88	763.25	797.7
	Brain uncertain & unspecified	4	3	7	0	2	2	2	2	4	0	3	3	1	4	5	1	6	7	1	1	2	9	21	30	1.37	2.83	2.11
	Neoplasms (Uncertain & unspecified, excluding brain)	4	14	18	2	21	23	11	17	28	13	31	44	27	38	65	46	30	76	30	35	65	133	186	319	19.84	25.09	22.21
	Brain & nervous system benign	2	3	5	3	4	7	7	8	15	12	11	23	13	14	27	12	10	22	8	15	23	57	65	122	8.46	8.77	8.64
	ALL CANCERS	79	256	335	111	355	466	247	424	671	842	936	1778	1700	1485	3185	1841	1457	3298	1214	1187	2401	6034	6100	12134	886.55	799.93	830.65
	^As of 2019, colorectal in situ cases are no longer of	collect	ed.			<u> </u>	l		<b>.</b>									<u> </u>					l	l	l	!		<u> </u>

<sup>^</sup> As of 2019, colorectal in situ cases are no longer collected

Standard Population: Manitoba 2011

<sup>\*</sup>Age standardized incidence rate per 100,000

### **Tumour Staging by Site**

## Staging on sites with more than 45 cases

#### LIP

Stage	Frequency	Percent	
Early/Intermediate	53	100	
Late	0	0.00	
Total	53	100	



#### COLORECTAL

Stage	Frequency	Percent	
Early/Intermediate	657	77.84	
Late	187	22.16	
Total	844	100	



#### TONGUE

Stage	Frequency	Percent	
Early/Intermediate	36	76.60	
Late	11	23.40	
Total	47	100	



#### COLON EXCLUDING RECTUM

Stage	Frequency	Percent	
Early/Intermediate	442	77.14	
Late	131	22.86	
Total	573	100	



#### **ESOPHAGUS**

Stage	Frequency	Percent	
Early/Intermediate	49	58.33	
Late	35	41.67	
Total	84	100	



#### **RECTUM & RECTOSIGMOID**

Stage	Frequency	Percent	
Early/Intermediate	215	79.34	
Late	56	20.66	
Total	271	100	



#### STOMACH

Stage	Frequency	Percent	
Early/Intermediate	71	59.66	
Late	48	40.34	
Total	119	100	



#### OTHER DIGESTIVE SYSTEM

Stage	Frequency	Percent	
Early/Intermediate	61	76.25	
Late	19	23.75	
Total	80	100	



#### **PANCREAS**

Stage	Frequency	Percent	
Early/Intermediate	80	45.98	
Late	94	54.02	
Total	174	100	



#### **LUNG & BRONCHUS**

Stage	Frequency	Percent	
Early/Intermediate	522	53.87	
Late	447	46.13	
Total	969	100	



#### SOFT TISSUE (INCL. HEART)

Stage	Frequency	Percent	
Early/Intermediate	55	91.67	
Late	5	8.33	
Total	60	100	



#### MELANOMA OF THE SKIN

Stage	Frequency	Percent	
Early/Intermediate	285	97.94	
Late	6	2.06	
Total	291	100	



<sup>\*</sup>Early/Intermediate includes non-metastatic and unknown stage cancer diagnoses, while Late stage includes metastatic cancer

<sup>\*\*</sup>In keeping with international coding conventions, all invasive brain tumors, multiple myeloma and non-CLL leukemia are considered unstageable using the AJCC TNM 8th edition staging system utilized by all population-based North American Cancer Registries.

#### LIVER

Stage	Frequency	Percent		
Early/Intermediate	67	83.75		
Late	13	16.25		
Total	80	100		



#### PROSTATE

Stage	Frequency	Percent	
Early/Intermediate	769	80.95	
Late	181	19.05	
Total	950	100	



#### BREAST

Stage	Frequency	Percent		
Early/Intermediate	957	94.75		/
Late	53	5.25		
Total	1010	100		



#### **TESTIS**

Stage	Frequency	Percent	
Early/Intermediate	45	100	
Late	0	0.00	
Total	45	100	



#### **CERVIX UTERI**

Stage	Frequency	Percent	
Early/Intermediate	51	92.73	
Late	4	7.27	
Total	55	100	



#### BLADDER

Stage	Frequency	Percent	
Early/Intermediate	131	88.51	
Late	17	11.49	
Total	148	100	



#### **CORPUS UTERI**

Stage	Frequency	Percent	
Early/Intermediate	249	92.57	
Late	20	7.43	
Total	269	100	



#### **KIDNEY**

Stage	Frequency	Percent	
Early/Intermediate	229	78.42	
Late	63	21.58	
Total	292	100	



#### OVARY

Stage	Frequency	Percent	
Early/Intermediate	61	74.39	
Late	21	25.61	
Total	82	100	



#### THYROID

Stage	Frequency	Percent	
Early/Intermediate	161	95.83	
Late	7	4.17	
Total	168	100	



### CHRONIC LYMPHOCYTIC LEUKEMIA/

SMALL LYMPHOTIC LYMPHOMA					
Stage	Frequency	Percent			
Early/Intermediate	46	77.97			
Late	13	22.03			
Total	59	100			



#### NON-HODGKIN I YMPHOMA

NOTE THOU BOTTON ET AND THOUSE				
Stage	Frequency	Percent		
Early/Intermediate	191	60.63		
Late	124	39.37		
Total	315	100		



<sup>\*\*</sup> Using Lugano and/or RAI stage footnote

<sup>\*</sup>Early/Intermediate includes non-metastatic and unknown stage cancer diagnoses, while Late stage includes metastatic cancer

<sup>\*\*</sup>In keeping with international coding conventions, all invasive brain tumors, multiple myeloma and non-CLL leukemia are considered unstageable using the AJCC TNM 8th edition staging system utilized by all population-based North American Cancer Registries.

## Deaths by Underlying Cause in Manitoba<sup>1</sup>

(Rate per 100,000)

	2019		2018		2017				
CAUSES OF DEATH	Number	Rate per MB Health Population	Rate per Statistics Canada Population*	Number	Rate per MB Health Population*	Rate per Statistics Canada Population*	Number	Rate per MB Health Population*	Rate per Statistics Canada Population*
Accidents (V01-X59, Y85-Y86)	497	36.2	36.0	379	27.9	28.0	422	31.1	31.5
Cancer (C00 - C97)	2,864	208.6	207.7	2,696	198.2	199.4	2,456	181.0	183.5
Cerebrovascular Disease (160 - 169)	595	43.3	43.1	526	38.7	38.9	561	41.3	41.9
Diabetes (E10 - E14)	331	24.1	24.0	315	23.2	23.3	276	20.3	20.6
Diseases of the heart (100 - 109, 111, 113, 120 - 125, 126 - 151)	2,076	151.2	150.5	1,951	143.4	144.3	1,883	138.8	140.7
Pneumonia (J12 - J18)	209	15.2	15.2	187	13.7	13.8	184	13.6	13.8
Intentional Self-Harm (X60 - X84, Y890)	192	14.0	13.9	219	16.1	16.2	166	12.2	12.4

#### Reference

<sup>1</sup>Vital Statistics Agency, 2019/20 Annual Report. Government of Manitoba; 2020. [cited March 06, 2023].

http://vitalstats.gov.mb.ca/pdf/2020\_vs\_annual\_report\_en.pdf

### Appendix 1

### INTERNATIONAL CLASSIFICATION OF DISEASES FOR ONCOLOGY

### **3rd Edition**

PRIMARY SITE	SITE/ CELL TYPE
Buccal cavity and pharynx	COO:C14
Lip	C000:C009
Tongue	C019:C029
Major salivary gland	C079:C089
Floor of mouth	C040:C049
Gum & other mouth	C030:C039, C050:C059, C060:C069
Nasopharynx	C110:C119
Oropharynx	C100:C109
Hypopharynx	C129, C130:C139
Other buccal cavity & pharynx	C090:C099, C140, C142:C148
Digestive system	C15:C26
Esophagus	C150:C159
Stomach	C160:C169
Small intestine	C170:C179
Colon excluding rectum	C180:C189, C260
Rectum & Rectosigmoid	C199, C209
Anus	C210:C212, C218
Liver	C220
Gallbladder	C239
Pancreas	C250:C259
Other digestive system	C240:C249, C221, C480, C481:C482, C268:C269
	C488
Respiratory system	(30:(39
Larynx	C320:C329
Lung & bronchus	C340:C349
Other respiratory system	C300:C301, C310:C319, C384, C339, C381:C383
	C388, C390:C399
Bones & joints	C400:C419
Soft tissue (including heart)	C380, C470:C479, C490:C499
Mesothelioma	9050:9055
Kaposi sarcoma	9140
Skin	C44
Melanomas of the skin	C440:C449 ( 8720:8790)
Other skin	C440:C449
Breast	C500:C509
Female genital system	C51:C58
Cervix uteri	C530:C539
Corpus uteri	C540:C549
Uterus, NOS	C559
Ovary	C569
Other female genital system	C529, C510:C519, C570:C589

PRIMARY SITE	SITE/ CELL TYPE
Male genital system	C60:C63
Prostate	C619
Testis	C620:C629
Penis	C600:C609
Other male genital system	C630:C639
Urinary system	C64:C68
Bladder (incl. <i>in situ</i> )	C670:C679
Kidney and renal pelvis	C649, C659
Ureter	C669
Other urinary system	C680:C689
Eye	C690:C699
Brain & other nervous system	C70:C72
Brain	C710:C719
Other nervous system	C710:C719 ( 953), C700:C709. C720:C729
Endocrine	C73:C75
Thyroid	C739
Other endocrine	C379, C740:C749, C750:C759
Lymphomas	
Hodgkin lymphoma	9650-9667
Non-Hodgkin lymphoma	9590-9597, 9670-9671, 9673, 9675, 9678-9680, 9684, 9687-9691, 9695, 9698-9702, 9705, 9708-9709, 9712, 9714-9719, 9724-9729, 9735, 9737, 9738
	9811-9818 (except C420, C421, C424) 9823 (except C420, C421, C424) 9827 (except C420, C421, C424) 9837 (except C420, C421, C424)
Myeloma	9731-9732, 9734
Leukemias	C42
Acute lymphocytic	9826, 9835-9836 9811-9818 (only C421) 9837 (only C421)
Chronic lymphocytic	9823 (only C421, if SLL C77)
Acute myeloid	9840, 9861, 9865-9867, 9869, 9871-9874, 9895- 9897, 9898, 9910-9911, 9920,
Acute monocytic	9891
Chronic myeloid	9863, 9875-9876, 9945-9946
Other	9733, 9742, 9800, 9801, 9805-9809, 9820, 9831- 9834, 9860, 9870, 9930, 9931, 9940, 9948, 9963, 9964 9827 (only C421)
Other, ill-defined, & unknown	9740-9741, 9750-9769, 9950, 9960-9962, 9965- 9967, 9970-9971, 9975, 9980, 9982-9987, 9989, 9991-9992 C420-C424 (except 9050-9055, 9140, 9590-9992) C760-C768 (except 9050-9055, 9140, 9590-9992) C770-C779 (except 9050-9055, 9140, 9590-9992)

#### **CONTACT DETAILS**

Epidemiology and Cancer Registry CancerCare Manitoba 675 McDermot Ave. Winnipeg, MB R3E 0V9 Main line: (204) 787-2174

Email: <a href="mailto:ccmbe;">CCMBepireg@cancercare.mb.ca</a>

#### TO CITE THIS REPORT

Department of Epidemiology and Cancer Registry, CancerCare Manitoba. "Cancer in Manitoba, 2019 Annual Statistical Report."

Find the Department of Epidemiology and Cancer Registry and data request guidelines online under the Research tab at <a href="https://www.cancercare.mb.ca">www.cancercare.mb.ca</a>

